EBPI - Environmental Bio-Detection Products Inc.

KRISHGEN BioSystems, (KRISHGEN) is a leading biotech company established to serve the research and biotech industry. Our goal is to enable breakthroughs in biological research, diagnostics, drug discovery and therapy development. The products we manufacture and supply range from proteins, assays, cell cultures, and other such tools.

We are committed to providing our customers with world-class solutions, service and support. Our track record of delivering quality products, at competitive prices lies with our distribution arrangement across the world. Our strength lies in our ability to understand technologies and support the scientists with technical backup and strong logistics.

We meet the needs of our bio-pharmaceutical and preclinical customers by providing a range of Research Use Only kits for researchers. We offer fully-optimized and validated products for ensuing preclinical and clinical studies.

Our ELISA kits and other assay reagents are an innovative cost effective tool for disease research, drug discovery & development, and molecular diagnostic test development.

We offer KRISHGEN CE Marked ELISA kits for Therapeutic Drug Monitoring like assays for Rituximab, Adalimumab, Eculizumab, Daratumumab, Trastuzumab and also for Incretin Mimetic - GLP1 Agonist Drugs like Exenatide, Liraglutide, Semaglutide, Lixisenatide.

We also have extensive ELISA kits for peptide drugs which are RUO including for Vasopressin, Octreotide amongst others.

We also distribute through our India office for leading companies worldwide in SE Asia and Middle East.

Some of our certifications include -
ISO 9008, ISO13485 certified.
CE Marked.
Authorized Economic Operator Status under WTO,
D&B rated.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements.

Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

ScreenCell was set-up with the belief that just enumerating Circulating Tumor Cells (CTCs) without easily characterizing them was not enough to allow the early detection of a disease and to potentially follow-up the cancer progression. So it designed and produced a simple but revolutionary technology allowing the fast and effective isolation of CTCs for a better cellular and molecular characterization, which is essential in cancer monitoring. This technology also contributes to the development of a new non-invasive approach to prenatal diagnosis.

Screencell is dedicated to create technologies allowing CTC to become potential end points in future oncology therapeutic arsenals, by filtering out healthy live tumor cells, thus enabling:
• Molecular biology
• Cell culture
• Enumeration and cytomorphology evaluation

For that matter, ScreenCell has designed a full range of devices (marked CE) compatible with existing In vitro Diagnostics (IVD) assays and platforms, with no need for any interface development. Our technology is now used in research studies, clinical trials, clinics and hospitals.

We truly believe that our technology can make a difference in cancer diagnostics by enabling clinicians to predict the possible metastases and to monitor the cancer therapy in real time.

Leaders of the Global Liquid Biopsy Revolution

As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).

SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Ares Genetics - a Vienna based startup - is revolutionizing how we address the global challenge of antimicrobial resistance (AMR).

To enable better infection control and more targeted patient care, Ares Genetics aims to provide unprecedented insight into AMR through next generation sequencing (NGS) and artificial intelligence (AI) powered solutions.
Innovative machine learning driven bioinformatics and the extensively curated ARESdb database comprehensively detect and interpret the genetic profile of pathogens.
Unlike conventional molecular assays, Ares Genetics solutions not only detect AMR markers but shed light on prevalence and diagnostic performance for these markers and predict how pathogens will respond to therapy.

Imprint: https://www.ares-genetics.com/imprint